




OVERVIEW

Axcella is pioneering a revolutionary therapeutic modality to restore health in patients with serious diseases by treating central metabolism dysregulation caused by disrupted amino acid biology. The company has developed a proprietary platform that identifies how disturbances in amino acids, as essential signaling molecules, lead to disease. The platform rapidly yields novel agents with the ability to restore normal amino acid homeostasis. Axcella has expeditiously translated its discoveries into agents that have been tested in 10 clinical trials to date and has lead clinical programs in intractable epilepsy, NASH and muscle atrophy. The company's discovery paradigm is oriented around clinical biology and uses human data to drive its platform. Axcella's platform is the first of its kind to identify key nodes to central metabolism, with the potential to extend its insights to over 2,000 diseases.

PIONEERING SYSTEMS PHARMACOLOGY

Biological pathways require cell-specific sets of amino acids to serve as critical signaling elements for essential biology, beyond their role as building blocks of proteins. Because amino acids are essential to many cellular processes, their proper balance is essential to health, their disruption core to disease, and the restoration of their homeostatic levels a previously unrecognized and untreated facet of disease. Axcella has developed the first tools to understand and augment this biology, which has broad-reaching impact across each disease in a precise and reproducible way.

Our lead clinical candidates have demonstrated in human and preclinical models an ability to bring homeostasis to dysregulated cells by **repairing** cellular function, **restoring** healthy pathways, and **regenerating** tissue and healthy organ function. Axcella expects to initiate multiple clinical studies in 2017 in NASH/NAFLD, intractable epilepsy, pre-diabetes, and other metabolic and neurologic diseases, to build on its success to date. Axcella has a rich preclinical pipeline, with over 40 programs, that is poised for rapid translation. The remarkable speed of development and the breadth of the Axcella pipeline has attracted a world-class syndicate of investors, board members and senior leaders.



CORPORATE FACTS

Status

Private

Headquarters

Cambridge, MA

Founded

2010, Flagship VentureLabs®

Funding Raised

\$132.5M

Leadership

- Chairman: Noubar Afeyan
- CEO: Robert Connelly
- CFO: Tom Leggett
- CMO: Chris Wright

Investors

- Flagship Pioneering
- Fidelity Research and Management Group
- Gurnet Point Capital
- Nestlé Health Science



Forbes Hottest Startups of 2015

Axcella Health Inc.
840 Memorial Drive, STE 3
Cambridge, MA 02139
857-320-2200

www.axcellhealth.com
bd@axcellahealth.com

